1 |
Costenbader KH, Desai A, Alarcón GS, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006 [J]. Arthritis Rheum, 2011, 63(6): 1681-1688.
|
2 |
Lightstone L. Lupus nephritis: where are we now [J]. Curr Opin Rheumatol, 2010, 22(3): 252-256.
|
3 |
Rovin BH, Parikh SV. Lupus nephritis: the evolving role of novel therapeutics [J]. Am J Kidney Dis, 2014, 63(4): 677-690.
|
4 |
杨静, 梁丹丹, 章海涛, 等. 狼疮性肾炎患者肾脏远期生存率及影响因素 [J]. 肾脏病与透析肾移植杂志, 2014, 23(5): 407-411, 406.
|
5 |
Muñoz LE, Lauber K, Schiller M, et al. The role of defective clearance of apoptotic cells in systemic autoimmunity [J]. Nat Rev Rheumatol, 2010, 6(5): 280-289.
|
6 |
Lech M, Anders HJ. The pathogenesis of lupus nephritis [J]. J Am Soc Nephrol, 2013, 24(9): 1357-1366.
|
7 |
Anders HJ, Rovin B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis [J]. Kidney Int, 2016, 90(3): 493-501.
|
8 |
Migliorini A, Anders HJ. A novel pathogenetic concept-antiviral immunity in lupus nephritis [J]. Nat Rev Nephrol, 2012, 8(3): 183-189.
|
9 |
Chang A, Henderson SG, Brandt D, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis [J]. J Immunol, 2011, 186(3): 1849-1860.
|
10 |
Flores-Mendoza G, Sansón SP, Rodríguez-Castro S, et al. Mechanisms of Tissue Injury in Lupus Nephritis [J]. Trends Mol Med, 2018, 24(4): 364-378.
|
11 |
Chung SA, Brown EE, Williams AH, et al. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus [J]. J Am Soc Nephrol, 2014, 25(12): 2859-2870.
|
12 |
Anders HJ, Fogo AB. Immunopathology of lupus nephritis [J]. Semin Immunopathol, 2014, 36(4): 443-459.
|
13 |
Kurts C, Panzer U, Anders HJ, et al. The immune system and kidney disease: basic concepts and clinical implications [J]. Nat Rev Immunol, 2013, 13(10): 738-753.
|
14 |
Honarpisheh M, Köhler P, von Rauchhaupt E, et al. The Involvement of MicroRNAs in Modulation of Innate and Adaptive Immunity in Systemic Lupus Erythematosus and Lupus Nephritis [J]. J Immunol Res, 2018, 2018: 4126106.
|
15 |
Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease [J]. Nat Rev Nephrol, 2016, 12(3): 133-146.
|
16 |
Moroni G, Depetri F, Ponticelli C. Lupus nephritis: When and how often to biopsy and what does it mean [J]. J Autoimmun, 2016, 74: 27-40.
|
17 |
Malvar A, Pirruccio P, Alberton V, et al. Histologic versus clinical remission in proliferative lupus nephritis [J]. Nephrol Dial Transplant, 2017, 32(8): 1338-1344.
|
18 |
Zickert A, Sundelin B, Svenungsson E, et al. Role of early repeated renal biopsies in lupus nephritis [J]. Lupus Sci Med, 2014, 1(1): e000018.
|
19 |
郭小芳, 隋满姝. 狼疮性肾炎自身抗体研究新进展 [J/CD]. 中华临床医师杂志(电子版), 2012, 6(1): 130-132.
|
20 |
Treamtrakanpon W, Tantivitayakul P, Benjachat T, et al. APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis [J]. Arthritis Res Ther, 2012, 14(6): R252.
|
21 |
Kopetschke K, Klocke J, Grießbach AS, et al. The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers [J]. Arthritis Res Ther, 2015, 17: 94.
|
22 |
Hasegawa H, Kohno M, Sasaki M, et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice [J]. Arthritis Rheum, 2003, 48(9): 2555-2566.
|
23 |
Zhang X, Jin M, Wu H, et al. Biomarkers of lupus nephritis determined by serial urine proteomics [J]. Kidney Int, 2008, 74(6): 799-807.
|
24 |
Wu H, Zeng J, Yin J, et al. Organ-specific biomarkers in lupus [J]. Autoimmun Rev, 2017, 16(4): 391-397.
|
25 |
张丽玲, 陈慎仁. 中性粒细胞明胶酶相关脂质运载蛋白的检测在狼疮性肾炎中的临床意义 [J/CD]. 中华临床医师杂志(电子版), 2010, 4(11): 2212-2214.
|
26 |
Dall′Era M. Treatment of lupus nephritis: current paradigms and emerging strategies [J]. Curr Opin Rheumatol, 2017, 29(3): 241-247.
|
27 |
Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study [J]. Arthritis Rheum, 2012, 64(4): 1215-1226.
|
28 |
李慧娟, 陈樱花, 胡伟新. 利妥昔单抗用于难治性狼疮性肾炎的治疗 [J]. 肾脏病与透析肾移植杂志, 2018, 27(1): 94-99.
|
29 |
Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase Ⅲ study [J]. Arthritis Rheum, 2013, 65(9): 2368-2379.
|
30 |
Zhang H, Liu Z, Huang L, et al. The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis [J]. Lupus, 2017, 26(9): 952-958.
|
31 |
Bao H, Liu ZH, Xie HL, et al. Successful treatment of class Ⅴ+Ⅳ lupus nephritis with multitarget therapy [J]. J Am Soc Nephrol, 2008, 19(10): 2001-2010.
|
32 |
Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial [J]. Ann Intern Med, 2015, 162(1): 18-26.
|
33 |
Zhang H, Liu Z, Zhou M, et al. Multitarget Therapy for Maintenance Treatment of Lupus Nephritis [J]. J Am Soc Nephrol, 2017, 28(12): 3671-3678.
|
34 |
Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis [J]. Arthritis Rheum, 2003, 48(3): 719-727.
|
35 |
Parikh SV, Rovin BH. Current and Emerging Therapies for Lupus Nephritis [J]. J Am Soc Nephrol, 2016, 27(10): 2929-2939.
|
36 |
Aringer M, Steiner G, Graninger WB, et al. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus [J]. Arthritis Rheum, 2007, 56(1): 274-279.
|
37 |
Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study [J]. Arthritis Rheum, 2010, 62(2): 542-552.
|
38 |
Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus [J]. Arthritis Rheumatol, 2017, 69(2): 376-386.
|
39 |
Karasawa K, Uchida K, Takabe T, et al. Recent Advances in Treatment Strategies for Lupus Nephritis [J]. Contrib Nephrol, 2018, 195: 42-50.
|